Michael J. Kemeter | MedReviews

<script language="JavaScript1.1" src="https://ad.doubleclick.net/ddm/adj/N9515.3206767MEDREVIEWS0/B22310636.252721090;abr=!ie;sz=728x90;ord=1;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=?"> <![CDATA[// ><!]]> </script>

Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score
Reviews in Urology
Volume 18, No 3 - 2016
Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Gene Genomic Prostate Score Versus Other Risk Stratification Methods
Original Research
Reviews in Urology
Volume 19, Number 4 - 2017
Balancing Confounding and Generalizability Using Observational, Real-world Data: 17-gene Genomic Prostate Score Assay Effect on Active Surveillance
Reviews in Urology
Volume 20, Number 2 - 2018